Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection

Critical Reviews in Oncology/Hematology

Volumn 79, Issue 3, 2011, Pages 251-264

  Power, Derek G ^a   Kemeny, Nancy E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Biologic therapy; Chemotherapy; Colorectal liver metastases; Conversion; Hepatic arterial infusion; Resection; Unresectable

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; DEXAMETHASONE; FLOXURIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PLACEBO;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BIOLOGICAL THERAPY; BLEEDING; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FATTY LIVER; FEBRILE NEUTROPENIA; HUMAN; HYPERTENSION; INTESTINE PERFORATION; LIVER METASTASIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; REVIEW; SIDE EFFECT; SKIN TOXICITY; STEATOSIS; STOMATITIS; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; VASCULAR LESION; VOMITING; WOUND HEALING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL THERAPY; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FLOXURIDINE; FLUOROURACIL; HEPATECTOMY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LEUCOVORIN; LIVER NEOPLASMS; ORGANOPLATINUM COMPOUNDS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79960942193     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.08.001     Document Type: Review

References (136)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Ferlay J., Autier P., Boniol M., et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18:581-592.
3. Kemeny N. Management of liver metastases from colorectal cancer. Oncology (Williston Park) 2006, 20:1161-1176.
4. Birgisson H., Smedh K. Effects of centralization of colorectal surgery on the outcome of patients with distal sigmoid colonic cancer. Dig Surg 2009, 26:169-175.
5. Renehan A.G., Saunders M.P., Schofield P.F., O'Dwyer S.T. Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer. Br J Surg 2005, 92:605-614.
6. Simunovic M., Rempel E., Theriault M.E., et al. Influence of hospital characteristics on operative death and survival of patients after major cancer surgery in Ontario. Can J Surg 2006, 49:251-258.
7. Hillner B.E., Smith T.J., Desch C.E. Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol 2000, 18:2327-2340.
8. NCCN NCCN clinical practice guidelines in oncology, v10 2010, National Comprehensive Cancer Network (NCCN).
9. Abdalla E.K., Vauthey J.N., Ellis L.M., et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004, 239:818-827.
10. Fernandez F.G., Drebin J.A., Linehan D.C., et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004, 240:438-450.
11. Rees M., Tekkis P.P., Welsh F.K., et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 2008, 247:125-135.
12. Tomlinson J.S., Jarnagin W.R., DeMatteo R.P., et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007, 25:4575-4580.
13. Choti M.A., Sitzmann J.V., Tiburi M.F., et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002, 235:759-766.
14. Adam R., Delvart V., Pascal G., et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004, 240:644-657. [discussion 648-57].
15. Wagner J.S., Adson M.A., Van Heerden J.A. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg 1984, 199:502-508.
16. Fuchs C.S., Marshall J., Mitchell E., et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007, 25:4779-4786.
17. Kemeny N.E., Melendez F.D., Capanu M., et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2009, 27:3465-3471.
18. Saltz L.B., Clarke S., Diaz-Rubio E., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26:2013-2019.
19. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004, 22:229-237.
20. Van Cutsem E., Kohne C.H., Hitre E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360:1408-1417.
21. Poston G.J., Figueras J., Giuliante F., et al. Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol 2008, 26:4828-4833.
22. Fong Y., Fortner J., Sun R.L., et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999, 230:309-318. [discussion 318-21].
23. Nordlinger B., Guiguet M., Vaillant J.C., et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996, 77:1254-1262.
24. Bilchik A.J., Poston G., Adam R., Choti M.A. Prognostic variables for resection of colorectal cancer hepatic metastases: an evolving paradigm. J Clin Oncol 2008, 26:5320-5321.
25. Adam R., Pascal G., Castaing D., et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?. Ann Surg 2004, 240:1052-1064.
26. Adam R., Wicherts D.A., de Haas R.J., et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality?. J Clin Oncol 2008, 26:1635-1641.
27. Kornprat P., Jarnagin W.R., Gonen M., et al. Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Ann Surg Oncol 2007, 14:1151-1160.
28. Thirion P., Michiels S., Pignon J.P., et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004, 22:3766-3775.
29. de Gramont A., Bosset J.F., Milan C., et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997, 15:808-815.
30. Goldberg R.M., Sargent D.J., Morton R.F., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004, 22:23-30.
31. Colucci G., Gebbia V., Paoletti G., et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005, 23:4866-4875.
32. Cassidy J., Clarke S., Diaz-Rubio E., et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008, 26:2006-2012.
33. Bajetta E., Di Bartolomeo M., Mariani L., et al. Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 2004, 100:279-287.
34. Borner M.M., Bernhard J., Dietrich D., et al. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol 2005, 16:282-288.
35. Bismuth H., Adam R., Levi F., et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996, 224:509-520. [discussion 502-20].
36. Giacchetti S., Itzhaki M., Gruia G., et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999, 10:663-669.
37. Adam R., Avisar E., Ariche A., et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001, 8:347-353.
38. Pozzo C., Basso M., Cassano A., et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004, 15:933-939.
39. Ho W.M., Ma B., Mok T., et al. Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the cancer therapeutic research group. Med Oncol 2005, 22:303-312.
40. Alberts S.R., Horvath W.L., Sternfeld W.C., et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005, 23:9243-9249.
41. Delaunoit T, Alberts S.R., Sargent D.J., et al. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol 2005, 16:425-429.
42. Masi G., Cupini S., Marcucci L., et al. Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol 2006, 13:58-65.
43. Barone C., Nuzzo G., Cassano A., et al. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer 2007, 97:1035-1039.
44. Ychou M., Viret F., Kramar A., et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol 2008, 62:195-201.
45. Masi G., Loupakis F., Pollina L., et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 2009, 249:420-425.
46. Folprecht G., Grothey A., Alberts S., et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005, 16:1311-1319.
47. Poston G., Adam R., Vauthey J.N. Downstaging or downsizing: time for a new staging system in advanced colorectal cancer?. J Clin Oncol 2006, 24:2702-2706.
48. Blazer D.G., Kishi Y., Maru D.M., et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008, 26:5344-5351.
49. Gallagher D.J., Zheng J., Capanu M., et al. Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases. Ann Surg Oncol 2009, 18:18.
50. Kemeny N.E., Capanu M., Huitzil-Melendez D., et al. Is neoadjuvant (neoadj) treatment necessary prior to liver resection in patients with resectable liver metastases (mets) from colorectal carcinoma (CRC) treated with post-resection hepatic arterial infusion (HAI) plus systemic (SYS) chemotherapy?. American Society of Clinical Oncology, annual proceedings 2007, [abstract # 14503].
51. Adam R., Wicherts D.A., de Haas R.J., et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?. J Clin Oncol 2009, 10:1829-1835.
52. Falcone A., Ricci S., Brunetti I., et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007, 25:1670-1676.
53. Kopetz S., Chang G.J., Overman M.J., et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009, 26:26.
54. Kozloff M., Yood M.U., Berlin J., et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009, 14:862-870.
55. Van Cutsem E., Rivera F., Berry S., et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009, 30:30.
56. Bokemeyer C., Bondarenko I., Makhson A., et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009, 27:663-671.
57. Folprecht G., Gruenberger T., Bechstein W.O., et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2009, 24:24.
58. Adam R., Aloia T., Levi F., et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 2007, 25:4593-4602.
59. Emmanouilides C., Sfakiotaki G., Androulakis N., et al. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer 2007, 7:91.
60. Tabernero J., Van Cutsem E., Diaz-Rubio E., et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007, 25:5225-5232.
61. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
62. Kabbinavar F.F., Hambleton J., Mass R.D., et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005, 23:3706-3712.
63. Ribero D., Wang H., Donadon M., et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007, 110:2761-2767.
64. Falcone A., Loupakis F., Cupini S., et al. FOLFOXIRI plus bevacizumab (BV) versus FOLFIRI plus BV as first-line treatment of metastatic colorectal cancer (MCRC): preliminary safety results of the phase III randomized TRIBE study by the Gruppo Oncologico Nord-Ovest (GONO). American Society of Clinical Oncology annual meeting 2010, [abstract 3543].
65. Masi G., Loupakis F., Baldi G., et al. First-line irinotecan, oxaliplatin and infusional 5FU/LV (FOLFOXIRI) in combination with bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts): a phase II study by the GONO Group. Gastrointestinal cancer symposium, American Society of Clinical Oncology 2008, [abstract 363].
66. Folprecht G., Schuette K., Stoehlmacher J., et al. Cetuximab and FOLFOXIRI: dose-escalation study in previously untreated patients with metastatic colorectal cancer. Gastrointestinal cancer symposium, American Society of Clinical Oncology 2010, [abstract 480].
67. Jacobs S.A., Allegra C.J., Wagman L.D., et al. Phase II study to determine surgical conversion rate in patients receiving neoadjuvant mFOLFOX7 plus cetuximab for unresectable wild-type KRAS colorectal cancer with metastases confined to liver. American Society of Clinical Oncology annual meeting 2010, [abstract: TPS 190].
68. Maughan T.S., Adams R., Smith C.G., et al. Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC): mature results of the MRC COIN trial. American Society of Clinical Oncology annual meeting 2010, [abstract 3502].
69. Lievre A., Bachet J.B., Boige V., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26:374-379.
70. Van Cutsem E., Lang I., Folprecht G., et al. Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): the influence of KRAS and BRAF biomarkers on outcome: Updated data from the CRYSTAL trial. Gastroinestinal Cancers Symposium 2010, [abstract #281].
71. Bokemeyer C., Kohne C., Rougier P., et al. Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. American Society of Clinical Oncology annual meeting 2010, [abstract: 3506].
72. Venook A.P., Blanke C.D., Niedzwiecki D., et al. Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma. Clin Colorectal Cancer 2007, 6:536-538.
73. Tol J., Koopman M., Cats A., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009, 360:563-572.
74. Hecht J.R., Mitchell E., Chidiac T., et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009, 27:672-680.
75. Nordlinger B., Sorbye H., Glimelius B., et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008, 371:1007-1016.
76. Ychou M., Hohenberger W., Thezenas S., et al. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 2009, 30:30.
77. Siena S., Cassidy J., Tabernero J., et al. Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial. Gastroinestinal Cancers Symposium 2010, [abstract #283].
78. Allegra C.J., Yothers G., O'Connell M.J., et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009, 27:3385-3390.
79. Breedis C., Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954, 30:969-977.
80. Ensminger W.D., Gyves J.W. Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol 1983, 10:176-182.
81. Wagner J.G., Gyves J.W., Stetson P.L., et al. Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. Cancer Res 1986, 46:1499-1506.
82. van Riel J.M., van Groeningen C.J., de Greve J., et al. Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver. Ann Oncol 2004, 15:59-63.
83. Balch C.M., Urist M.M. Intraarterial chemotherapy for colorectal liver metastases and hepatomas using a totally implantable drug infusion pump. Recent Results Cancer Res 1986, 100:234-247.
84. Kemeny M.M., Goldberg D., Beatty J.D., et al. Results of a prospective randomized trial of continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries. Cancer 1986, 57:492-498.
85. Schwartz S.I., Jones L.S., McCune C.S. Assessment of treatment of intrahepatic malignancies using chemotherapy via an implantable pump. Ann Surg 1985, 201:560-567.
86. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis group in cancer. J Clin Oncol 1998, 16:301-308.
87. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-analysis group in cancer. J Clin Oncol 1998, 16:3537-3541.
88. Chang A.E., Schneider P.D., Sugarbaker P.H., et al. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987, 206:685-693.
89. Kemeny N., Daly J., Reichman B., et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987, 107:459-465.
90. Hohn D.C., Stagg R.J., Friedman M.A., et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 1989, 7:1646-1654.
91. Martin J.K., O'Connell M.J., Wieand H.S., et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 1990, 125:1022-1027.
92. Wagman L.D., Kemeny M.M., Leong L., et al. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol 1990, 8:1885-1893.
93. Rougier P., Laplanche A., Huguier M., et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992, 10:1112-1118.
94. Allen-Mersh T.G., Earlam S., Fordy C., et al. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 1994, 344:1255-1260.
95. Lorenz M., Muller H.H. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2000, 18:243-254.
96. Kerr D.J., McArdle C.S., Ledermann J., et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet 2003, 361:368-373.
97. Kemeny N.E., Niedzwiecki D., Hollis D.R., et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006, 24:1395-1403.
98. Downs S.H., Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998, 52:377-384.
99. Mocellin S., Pilati P., Lise M., Nitti D. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era?. J Clin Oncol 2007, 25:5649-5654.
100. Cancer M-AGi. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. Meta-analysis group in cancer. J Natl Cancer Inst 1996, 88:252-258.
101. Harmantas A., Rotstein L.E., Langer B. Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Is there a survival difference? Meta-analysis of the published literature. Cancer 1996, 78:1639-1645.
102. Kemeny N., Conti J.A., Cohen A., et al. Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol 1994, 12:2288-2295.
103. Kemeny N., Seiter K., Niedzwiecki D., et al. A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer 1992, 69:327-334.
104. Bokemeyer C., Bondarenko I., Hartmann J.T., et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience. J Clin Oncol 2008, 26. [abs 4000].
105. Kemeny N., Gonen M., Sullivan D., et al. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol 2001, 19:2687-2695.
106. Kemeny N., Jarnagin W., Paty P., et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 2005, 23:4888-4896.
107. Ducreux M., Ychou M., Laplanche A., et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 2005, 23:4881-4887.
108. Gallagher D.J., Capanu M., Raggio G., Kemeny N. Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis. Ann Oncol 2007, 24:24.
109. Boige V., Malka D., Elias D., et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol 2008, 15:219-226.
110. Bouchahda M., Adam R., Giacchetti S., et al. Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer. Cancer 2009, 115:4990-4999.
111. Goere D., Deshaies I., de Baere T., et al. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg 2010, 10:10.
112. Kemeny N., Fata F. Hepatic-arterial chemotherapy. Lancet Oncol 2001, 2:418-428.
113. Kemeny N.E., Fong Y., Jarnagin W.R., et al. A randomized phase II study of hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. American Society of Clinical Oncology annual meeting 2010, [abstract #3557].
114. Benoist S., Brouquet A., Penna C., et al. Complete response of colorectal liver metastases after chemotherapy: Does it mean cure?. J Clin Oncol 2006, 24:3939-3945.
115. Auer R.C., White R.R., Kemeny N., et al. Predictors of a true complete response among disappearing liver metastases from colorectal cancer following chemotherapy. Cancer 2010, 116(6):1502-1509.
116. Elias D., Goere D., Boige V., et al. Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol 2007, 14:3188-3194.
117. Goshen E., Davidson T., Zwas S.T., Aderka D. PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan. Technol Cancer Res Treat 2006, 5:37-43.
118. Wahl R.L., Jacene H., Kasamon Y., Lodge M.A. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009, 50(Suppl 1):122S-150S.
119. Tan M.C., Linehan D.C., Hawkins W.G., et al. Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg 2007, 11:1112-1119.
120. Small R.M., Lubezky N., Shmueli E., et al. Response to chemotherapy predicts survival following resection of hepatic colorectal metastases in patients treated with neoadjuvant therapy. J Surg Oncol 2009, 99:93-98.
121. Lin M., Wong K., Ng W.L., et al. Positron emission tomography and colorectal cancer. Crit Rev Oncol Hematol 2010, 7.
122. Chun Y.S., Laurent A., Maru D., Vauthey J.N. Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol 2009, 10:278-286.
123. Kemeny N. Presurgical chemotherapy in patients being considered for liver resection. Oncologist 2007, 12:825-839.
124. Alberts S.R., Wagman L.D. Chemotherapy for colorectal cancer liver metastases. Oncologist 2008, 13:1063-1073.
125. Aloia T., Sebagh M., Plasse M., et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006, 24:4983-4990.
126. Vauthey J.N., Pawlik T.M., Ribero D., et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006, 24:2065-2072.
127. Nordlinger B., Van Cutsem E., Gruenberger T., et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 2009, 20:985-992.
128. Montagnani F., Chiriatti A., Turrisi G., et al. A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity. Colorectal Dis 2010, 12:12.
129. Klinger M., Eipeldauer S., Hacker S., et al. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol 2009, 4:4.
130. Scappaticci F.A., Fehrenbacher L., Cartwright T., et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005, 91:173-180.
131. Kesmodel S.B., Ellis L.M., Lin E., et al. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 2008, 26:5254-5260.
132. Reddy S.K., Morse M.A., Hurwitz H.I., et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 2008, 206:96-106.
133. Aussilhou B., Dokmak S., Faivre S., et al. Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Ann Surg Oncol 2009, 16:1553-1559.
134. Natarajan A., Wagner B., Sibilia M. The EGF receptor is required for efficient liver regeneration. Proc Natl Acad Sci USA 2007, 104:17081-17086.
135. Power D.G., Kemeny N.E. The role of floxuridine in metastatic liver disease. Mol Cancer Ther 2009, 21:21.
136. Allen P.J., Nissan A., Picon A.I., et al. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg 2005, 201:57-65.